TXA-709, active metabolite TXA-707

Class: FtsZ inhibitor

Spectrum of activity:	Gram-positive
Details of activity:	Inhibits the Filamentous Temperature Sensitive mutant Z (FtsZ), a cytoplasmic essential protein in the cell division process.
Description:	Synthetic compound; methoxybenzamide; oral administration
Institute where first reported:	TAXIS Pharmaceuticals
Year first mentioned:	2015
Highest developmental phase:	Phase 1
Development status:	Active

Chemical structure(s):
Canonical SMILES:	CN1CCC(CC1)C(=O)NC(=O)C2=C(C(=CC=C2F)OCC3=NC4=C(N=CC(=C4)C(F)(F)F)S3)F
Isomeric SMILES:	CN1CCC(C(NC(C2=C(F)C(OCC3=NC4=C(S3)N=CC(C(F)(F)F)=C4)=CC=C2F)=O)=O)CC1
InChI:	InChI=1S/C22H19F5N4O3S/c1-31-6-4-11(5-7-31)19(32)30-20(33)17-13(23)2-3-15(18(17)24)34-10-16-29-14-8-12(22(25,26)27)9-28-21(14)35-16/h2-3,8-9,11H,4-7,10H2,1H3,(H,30,32,33)
InChI Key:	LOTYKTRNFDRNAY-UHFFFAOYSA-N

External links:
Guide to Pharmacology:	TXA709
Main Source:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505295/
Citation:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576109/